First ALS patients receive experimental gene therapy in groundbreaking safety trial
NCT ID NCT07401121
Summary
This early-stage study is testing the safety of a new gene therapy called CTx1000 in people with ALS. The therapy aims to target a protein called TDP-43 that builds up in ALS. Researchers will give a single dose to 15 participants and closely monitor for side effects while also checking if it might help slow disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Macquarie University Hospital
RECRUITINGSydney, New South Wales, 2109, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.